These agents target the CFTR protein defect by potentiating (ivacaftor) or correcting (elexacaftor, tezacaftor, lumacaftor) its function [7] and are used in 83% of adults with CF in Germany [2]. This evidence concerns the gene CFTR and cystic fibrosis.